Novavax (NASDAQ:NVAX) stock could trade in the $100 billion market capitalization range like BioNTech (NASDAQ:BNTX) or Moderna (NASDAQ:MRNA). Except, unlike those companies, Novavax has not yet delivered.
Source: Ascannio/Shutterstock.com
It might be among the most-watched firms that did not yet bring a Covid-19 vaccine to market.
Chances are low that it will slump like Altimmune (NASDAQ:ALT) after it discontinued its nasal Covid-19 vaccine.
By comparison, Inovio Pharmaceuticals (NASDAQ:INO) is on the mend after Brazil approved its vaccine candidate.
If....More>>>